BioPharmSignal logoBioPharmSignal

Biotech News

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

Sutro Biopharma (STRO)Sutro BiopharmaConference / presentation

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 17th Annual World ADC Conference, taking place in San Diego, October 12-15, 2026.

Related news

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

STROSutro Biopharma2026-09-29 12:00 EST

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

PRLDPrelude Therapeutics2026-09-11 11:01 EST

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

ACRVAcrivon Therapeutics2026-09-02 12:00 EST

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

View all latest news

Sutro Biopharma

Next-Generation ADC Company Sutro Biopharma develops site-specific and novel-format antibody-drug conjugates for cancer. Its cell-free platform enables optimization of antibodies, linkers, and payloads and supports both single-payload and dual-payload ADC designs. Wholly Owned ADC Pipeline STRO-004 is a Tissue Factor-targeting ADC with a...

Recent company news

STROSutro Biopharma2026-10-12 12:00 EST

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

STROSutro Biopharma2026-09-29 12:00 EST

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

STROSutro Biopharma2026-08-12 11:00 EST

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

STROSutro Biopharma2026-05-14 20:05 EST

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

STROSutro Biopharma2026-04-19 23:45 EST

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

Stock data

Close
10.79 USD
Market cap
404.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States